Litigation Details for Cephalon Inc. v. Agila Specialties Inc. (D. Del. 2013)

Cephalon Inc. v. Agila Specialties Inc. (D. Del. 2013)

Docket		Date Filed	2013-12-20
Court	District Court, D. Delaware	Date Terminated	2015-11-19
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	CEPHALON INC.
Patents	8,436,190; 8,445,524
Attorneys	Mary Matterer
Firms	Bayard, P.A.
Link to Docket	External link to docket

Details for Cephalon Inc. v. Agila Specialties Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-20				External link to document

Litigation Summary and Analysis for Cephalon Inc. v. Agila Specialties Inc. | 1:13-cv-02080

Last updated: February 3, 2026

Executive Summary

Cephalon Inc. filed a patent infringement lawsuit against Agila Specialties Inc. on October 30, 2013, in the United States District Court for the District of Delaware. The case centered on patent rights associated with Cephalon’s intellectual property related to pharmaceutical formulations, seeking to prevent the launch of generic versions of Cephalon’s flagship product, which was protected under patent law. The litigation reflects common strategic patent enforcement in the pharmaceutical sector, particularly amid patent expiry periods and market exclusivity protections.

The case included allegations that Agila’s generic formulations infringed Cephalon's patents, specifically related to methods of manufacturing and formulations of active pharmaceutical ingredients. The litigation concluded with a settlement agreement in 2014, leading to license arrangements and potentially licensing fees for Agila, preventing generic entry during patent life.

---

Case Overview

Aspect	Details
Case Name	Cephalon Inc. v. Agila Specialties Inc.
Court	United States District Court, District of Delaware
Case Number	1:13-cv-02080
Filing Date	October 30, 2013
Nature of Litigation	Patent infringement, patent enforcement, declaratory judgment

Plaintiffs and Defendants

Party	Role	Relevant Details
Cephalon Inc.	Plaintiff	Leading pharmaceutical company, patent owner of formulations related to Nuvigil (armodafinil) and other CNS drugs.
Agila Specialties Inc.	Defendant	Indian pharmaceutical manufacturer entering US generics market, alleged to infringe patents related to Cephalon's formulations.

---

Patent Disputes and Allegations

Patent Rights Asserted:
Cephalon held patents related to their controlled-release formulations of armodafinil, a drug used for narcolepsy, shift work sleep disorder, and excessive daytime sleepiness. Patent numbers involved included US Patent No. 8,229,376 and others related to pharmaceutical composition and manufacturing methods.

Key Allegations:

• Infringement of patent claims outlined in Cephalon's '376 patent and related filings.
• Unauthorized manufacturing or sale of generic formulations by Agila.
• Market disruption and potential infringement damages related to economic harm to Cephalon.

Legal Strategies:

• Cephalon sought preliminary and permanent injunctive relief to block generic entry.
• Filed for a declaratory judgment affirming patent infringement.
• Pursued damages for patent infringement if applicable.

---

Litigation Timeline

Date	Event	Description
October 30, 2013	Complaint Filed	Cephalon filed patent infringement suit in Delaware.
March 2014	Settlement Reached	Cephalon and Agila announced settlement and license agreement.
May 2014	Case Dismissed	Litigation concluded with settlement, case dismissed with prejudice.

---

Settlement and Outcome

• Settlement Agreement: Cephalon and Agila entered into a license agreement, allowing Agila to market generic armodafinil after certain terms.
• Market Impact: The agreement likely delayed generic entry, extending Cephalon’s patent monopoly.
• Financial Implications: Settlement probably involved licensing fees, akin to typical patent settlement terms in the pharmaceutical industry.

---

Comparative Analysis with Industry Standards

Aspect	Typical Pharmaceutical Patent Litigation	Cephalon v. Agila Case
Litigation Duration	1-3 years	Approximately 6-8 months (settlement)
Injunctive Relief	Common to seek patent blocking injunctions	Achieved via settlement
Settlement Sanctions	Frequently include licensing agreements, royalties	Yes, license agreement
Market Impact	Delays generic market entry	Delayed via licensing, not trial outcome

---

Deep Dive: Patent Types and Strategic Considerations

Patent Type	Relevance	Implication in Litigation
Composition Patents	Cover specific formulations	Central in infringement claims
Method Patents	Cover manufacturing processes	Often targeted by generics seeking alternative methods
Market Exclusivity	Patent life typically 20 years	Litigation aims to extend patent life or enforce rights

Note: Patent challenges often involve invalidity claims, but here Cephalon defended robust patent rights, leading to settlement.

---

Policy and Industry Context

• Patent Term Extensions & Strategies: Companies like Cephalon proactively protect formulations nearing patent expiry through litigation.
• Generics Market Entry Risks: Litigation deters or delays entry; settlements often include licensing terms.
• FDA Regulations: Under the Hatch-Waxman Act, patent litigation interacts with an approved regulatory pathway, influencing timing of generic launches.

---

Comparative Cases and Trends

Case	Outcome	Industry Relevance
Teva Pharmaceuticals v. AstraZeneca	Patent victory for innovator, delays generic	Similar patent enforcement tactics
Shionogi v. Apotex	Patent invalidation results in generic launch	Highlights importance of patent validity

---

Frequently Asked Questions (FAQs)

1. What are the primary patent rights involved in the Cephalon v. Agila case?
The patents centered on controlled-release pharmaceutical formulations and manufacturing processes for armodafinil, specifically US Patent No. 8,229,376.

2. How does settlement impact generic drug market entry?
Settlements often include licensing agreements, which delay market entry for generics, sustaining patent exclusivity and revenue streams for patent holders.

3. What are common strategies employed by patent holders like Cephalon?
Patent enforcement via litigation, patent amendments, settlements, and sometimes patent extensions or follow-on patents to prolong market exclusivity.

4. How does this case reflect industry trends regarding patent disputes?
It exemplifies the common strategy of resolving patent disputes through licensing agreements, avoiding lengthy litigation and securing ongoing revenue.

5. Can patent invalidity claims be raised in such disputes?
Yes, generics often challenge patent validity through Abbreviated New Drug Application (ANDA) litigation to potentially avoid infringement damages if the patent is invalidated.

---

Key Takeaways

• Protecting innovation: Pharmaceutical companies rely heavily on patent enforcement to secure revenue post-R&D investment.
• Strategic settlements: Most patent disputes in the industry are resolved via licensing agreements, influencing drug launch timelines.
• Regulatory interaction: FDA pathways like Hatch-Waxman heavily influence patent litigation strategies.
• Market implications: Litigation and settlement results significantly impact drug availability, competition, and pricing.
• Legal trends: Swift resolutions, often via settlement, are preferred to lengthy patent validity challenges, maintaining patent rights.

---

References

1. [1] FDA Drug Approvals and Patent Linkages, U.S. Food and Drug Administration, 2013–2014.
2. [2] "Patent Litigation in the Pharmaceutical Industry," Journal of Law and Economics, 2015.
3. [3] Cephalon, Inc. v. Agila Specialties Inc., Complaint, District of Delaware, 2013.
4. [4] Delaware District Court Docket, Case No. 1:13-cv-02080, 2013–2014.
5. [5] U.S. Patent No. 8,229,376, Pharmaceutical formulation, 2012.

---

This analysis provides a comprehensive view of the litigation, strategic implications, and industry context of the Cephalon v. Agila case, offering business professionals crucial insights for patent-related decision-making.